Key Takeaways
- Silo Pharma shares rocketed 47.55% in extended trading Monday, reaching $0.52
- Europe’s Patent Office delivered a Rule 71(3) notice indicating plans to approve a patent for the company’s PTSD prevention treatment
- The intellectual property protects therapeutic methods utilizing serotonin 4 (5-HT4) receptor agonists to block stress-related fear and depression
- Columbia University holds the original patent, which SILO has secured through an exclusive licensing agreement for key European territories
- The biotech company maintains a market capitalization around $4.98 million and trades significantly under its yearly peak of $1.18
Shares of Silo Pharma experienced a dramatic aftermarket rally Monday following positive developments from the European Patent Office (EPO), which delivered a Rule 71(3) notification — a procedural step indicating formal plans to award patent protection — for the company’s groundbreaking preventative PTSD treatment.
The intellectual property filing, designated “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” focuses on the serotonin 4 (5-HT4) receptor mechanism. This therapeutic strategy aims to block stress-triggered fear responses and depressive symptoms proactively, representing a departure from conventional post-symptom interventions.
Columbia University originally developed the patent, which Silo Pharma has obtained via exclusive licensing rights. The company is currently assessing Unitary Patent safeguards and country-specific validations throughout Europe to maximize territorial reach.
Chief Executive Eric Weisblum described the development as a “high-value milestone” that bolsters the organization’s worldwide intellectual property portfolio.
Patent Protection Details
The approved claims encompass therapeutic protocols for blocking stress-triggered fear responses, depression-like symptoms, and associated mood disorders through specific 5-HT4 receptor agonist compounds.
This represents a paradigm shift from conventional PTSD therapies, which address manifestations post-development. Silo’s methodology concentrates on strengthening psychological resilience proactively.
The intellectual property directly underpins SPC-15, the organization’s primary PTSD candidate. The company’s development portfolio additionally features SP-26 for fibromyalgia and persistent pain management, alongside early-stage compounds targeting Alzheimer’s pathology.
Trading Performance Analysis
SILO concluded Monday’s standard trading session at $0.36 before jumping to $0.52 during after-hours activity — representing a 47.55% gain.
The equity’s yearly trading range illustrates substantial volatility: shares reached $1.18 at their zenith and bottomed at $0.22 throughout the past twelve months. This represents considerable price fluctuation for an enterprise valued just below $5 million.
Benzinga’s technical indicators positioned SILO with unfavorable momentum metrics across multiple timeframes prior to Monday’s announcement.
The aftermarket surge pushed shares back above the $0.50 threshold for the first time in recent sessions, although the price remains well below its annual high.
Once the EPO formally issues the patent, Silo’s PTSD treatment is anticipated to receive protection throughout significant European commercial territories.
